---
aliases: [TXG, 10x]
---
#actor #genomics #singlecell #usa #public

**10x Genomics** — Single-cell and spatial genomics leader. Chromium platform. Research tools for cell biology.

---

## Why 10x Genomics matters

| Metric | Value |
|--------|-------|
| Ticker | TXG |
| Market cap | ~$2B |
| Founded | 2012 |
| HQ | Pleasanton, CA |
| Focus | Single-cell & spatial biology |

---

## Technology platforms

### Chromium (Single-cell)

| Feature | Detail |
|---------|--------|
| Application | Single-cell gene expression |
| Method | Droplet-based partitioning |
| Throughput | 10,000+ cells per run |
| Market position | **Category leader** |

### Visium (Spatial)

| Feature | Detail |
|---------|--------|
| Application | Spatial transcriptomics |
| Method | Tissue sections on slides |
| Resolution | 55 μm spots |
| Use case | Tumor microenvironment, tissue architecture |

### Xenium (In Situ)

| Feature | Detail |
|---------|--------|
| Application | In situ gene expression |
| Method | Single-cell resolution in tissue |
| Resolution | Subcellular |
| Status | Growing adoption |

---

## Business model

| Revenue stream | Detail |
|----------------|--------|
| Instruments | Chromium, Xenium platforms |
| Consumables | Recurring per experiment |
| Software | Analysis tools |

**Customer base:** Academic research, pharma R&D, biotech.

---

## Market applications

| Application | Use case |
|-------------|----------|
| Oncology | Tumor heterogeneity, immune profiling |
| Immunology | Cell atlas, immune response |
| Neuroscience | Brain cell types, disease |
| Drug discovery | Target ID, mechanism of action |
| Developmental biology | Cell lineage, differentiation |

---

## Competitive landscape

| Competitor | Technology |
|------------|------------|
| **10x Genomics** | Droplet single-cell, spatial |
| BD Biosciences | Rhapsody (antibody-based) |
| Nanostring | GeoMx (spatial protein/RNA) |
| Vizgen | MERFISH (in situ) |
| Parse Biosciences | Combinatorial single-cell |

**Moat:** Installed base, ease of use, ecosystem.

---

## Challenges

| Issue | Impact |
|-------|--------|
| Research funding | NIH uncertainty |
| Competition | Parse, Vizgen gaining |
| Valuation | Significant decline from peak |
| Profitability | Still investing heavily |

---

## Investment case

**Bull:**
- Category creator and leader
- Spatial genomics = next frontier
- Essential research tool
- Pharma partnerships
- Recurring consumables model

**Bear:**
- Research-only (no clinical revenue)
- NIH funding headwind
- Competition intensifying
- Unprofitable
- Stock down 80%+ from peak

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | TXG |
| Market cap | ~$2B |
| Focus | Single-cell, spatial |
| Customers | Research institutions |

---

## Related

- [[Illumina]] — sequencing partner
- [[Genomics]] — sector concept
- [[AI drug discovery]] — application
- [[Biopharma]] — customer base

---

## Sources

- [10x Genomics](https://www.10xgenomics.com/)
- Company filings

*Created 2026-01-09*
